Corbus Completes Dose Escalation in Phase 1 Trial of Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an oncology and obesity-focused company, has announced the completion of patient enrollment for the dose escalation phase of its Phase 1 clinical trial of CRB-701 (SYS6002). This open-label study, identified as NCT06265727, is conducted in the United States and the United Kingdom.

The Phase 1 trial of CRB-701 is divided into three segments. Part A, which focuses on dose escalation, is evaluating four pre-set dosage levels: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg. This will be followed by Part B (dose optimization) and Part C (dose expansion). The primary goal is to identify recommended or optimized doses and to gather preliminary efficacy data. The company anticipates releasing the initial data from the dose escalation phase in the first quarter of 2025.

CRB-701 (SYS6002) is an advanced antibody-drug-conjugate (ADC) targeting Nectin-4, a tumor-associated antigen clinically validated in urothelial cancer. This ADC includes a site-specific, cleavable linker and a homogeneous drug antibody ratio of 2, using MMAE as the payload.

Corbus Pharmaceuticals Holdings, Inc., based in Norwood, Massachusetts, is dedicated to addressing serious illnesses through innovative scientific methods focused on well-understood biological pathways. The company's diverse portfolio comprises several key pipeline products including:

- **CRB-701**: A next-generation ADC aimed at targeting Nectin-4 on cancer cells to deliver a cytotoxic payload.
- **CRB-601**: An anti-integrin monoclonal antibody designed to inhibit the activation of TGFβ expressed on cancer cells.
- **CRB-913**: A highly peripherally restricted CB1 receptor inverse agonist developed for the treatment of obesity.

For more detailed information about Corbus and its scientific endeavors, interested parties can visit their website at corbuspharma.com.

Corbus continues to align its mission with addressing critical health challenges, focusing on breakthrough treatments that modify biological pathways known to play a role in severe diseases. The completion of the enrollment for the dose escalation study of CRB-701 marks a significant milestone in the company’s progress towards developing effective treatments for cancers expressing high levels of Nectin-4.